BIOPHYTIS (EPA:ALBPS) - Biophytis to Participate in Upcoming Investor and Partnering Conferences During J.P. Morgan Week 2021

Transparency directive : regulatory news

07/01/2021 08:00

Press Release

Biophytis to Participate in Upcoming Investor & Partnering Conferences During
                            J.P. Morgan Week 2021

Paris (France), Cambridge (Massachusetts, United States), January 7th, 2020,
8:00 a.m. CET - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage
biotechnology company developing therapeutics that slow the degenerative
processes associated with aging and improve functional outcomes for patients
suffering from age-related diseases, including severe respiratory failure in
patients suffering from COVID-19, today announces its management will
participate and meet with investors and potential partners at the following
upcoming virtual meetings:

-  H.C. Wainwright Bioconnect 2021 Conference January 11 - 14, 2021

-  BIO Partnering @ JPM Week 2021 January 11 - 15, 2021

-  BIOTECH Showcase @JPM Week 2021 January 11 - 15, 2021

About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company specialized in the
development of therapeutics that slow the degenerative processes associated
with aging and improve functional outcomes for patients suffering from
age-related diseases, including severe respiratory failure in patients
suffering from COVID-19.

Sarconeos (BIO101), our leading drug candidate, is a small molecule,
administered orally, being developed as a treatment for sarcopenia in a Phase 2
clinical trial in the US and Europe (SARA-INT). It is also being studied in a
clinical two-part Phase 2/3 study (COVA) for the treatment of severe
respiratory manifestations of COVID-19 in Europe, Latin America and the US.

A pediatric formulation of Sarconeos (BIO101) is being developed for the
treatment of Duchenne Muscular Dystrophy (DMD).

The company is based in Paris, France, and Cambridge, Massachusetts. The
company's common shares are listed on the Euronext Growth Paris market (Ticker:
ALBPS -ISIN: FR0012816825). For more information visit www.biophytis.com

Disclaimer
This press release contains forward-looking statements. While the Company
considers its projections to be based on reasonable assumptions, these
forward-looking statements may be called into question by a number of hazards
and uncertainties, so that actual results may differ materially from those
anticipated in such forward-looking statements. For a description of the risks
and uncertainties likely to affect the results, BIOPHYTIS' financial position,
performance or achievements and thus cause a change from the forward-looking
statements, please refer to the "Risk Factors" section of the Company's Annual
2019 Report and the Company's Half Year 2020 Report available on BIOPHYTIS
website (www.biophytis.com).

This press release, and the information contained in it, does not constitute an
offer to sell or subscribe, nor the solicitation of a purchase or subscription
order, of BIOPHYTIS shares in any country. The elements contained in this
communication may contain forward-looking information involving risks and
uncertainties. The Company's actual achievements may differ materially from
those anticipated in this information due to different risk and uncertainty
factors. This press release was written in French and English; If there is a
difference between the texts, the French version will prevail.

Biophytis Contact for Investor Relations
Evelyne Nguyen, CFO
evelyne.nguyen@biophytis.com

Media contact
Citigate Dewe Rogerson
Sylvie Berrebi/ Nathaniel Dahan/ David Dible / Quentin Dussart
biophytis@citigatedewerogerson.com
+44 (0) 20 7638 9571 / +33 (0)1 55 30 70 91

Source: Biophytis

BIOPHYTIS's latest news

14/05/2024 07:00

BIOPHYTIS (EPA:ALBPS) - Biophytis to Participate in Upcoming Investor and Partnering Conferences During J.P. Morgan Week 2021

Transparency directive : regulatory news

BIOPHYTIS's latest news

Other stories